Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas. Show more

Location: 2617 Bissonnet Street, Houston, TX, 77005, United States | Website: https://www.alaunos.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

8.411M

52 Wk Range

$1.31 - $7.00

Previous Close

$5.13

Open

$5.04

Volume

56,249

Day Range

$4.68 - $5.09

Enterprise Value

8.092M

Cash

319K

Avg Qtr Burn

-956.5K

Insider Ownership

9.18%

Institutional Own.

3.59%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.